Waters Corporation, a global leader in analytical instruments, software, and laboratory technologies, will combine with Becton Dickinson’s (BD) Biosciences & Diagnostic Solutions division in a $17.5 billion Reverse Morris Trust transaction.
- BD will spin off the biosciences and diagnostics unit to its shareholders, who will then receive shares in the combined Waters entity.
- Waters shareholders retain about 8 % of the new company; BD shareholders receive approximately 39.2 %, along with ~$4 billion cash distribution.
- Waters assumes $4 billion of debt, resulting in a projected net-debt-to-adjusted EBITDA leverage of ~2.3× at closing.
- Transaction closing is anticipated by end of Q1 2026, pending regulatory and shareholder approvals.
Companies Involved
Waters Corporation
- Based in Milford, Massachusetts, Waters is renowned for its liquid chromatography, mass spectrometry, separations technology, and informatics platforms.
- Serves pharmaceuticals, biotech, environmental, food and beverage and academic markets with high-margin consumables and recurring-service revenue.
- Leadership: CEO Udit Batra and Chairman Flemming Ørnskov.
Becton Dickinson (BD)
- A leading global med‑tech company focused on medical devices, drug delivery systems, and healthcare procedures.
- Its Biosciences & Diagnostic Solutions division provides flow cytometry reagents/instruments, molecular & microbiology diagnostics, cervical cancer screening, and multiomics tools, generating around $3.4 billion revenue and $925 million EBITDA in 2025.
- BD decided to divest this division in February 2025 to sharpen its focus on core device businesses.
Deal Structure & Financial Mechanics
Structure:
The Reverse Morris Trust combines a tax-free spin-off with a merger. BD spins out the subsidiary to shareholders and merges it with a Waters subsidiary, circumventing taxable gain on direct sale.
Valuation & Ownership:
- Implied valuation multiples: The deal implies a valuation multiple of approximately 5× revenue, based on the 2025 projected revenue of $3.4 billion for BD’s Biosciences & Diagnostic Solutions unit and the $17.5 billion transaction value.
- Ownership split: Waters shareholders ~60.8 %, BD shareholders ~39.2 %.
Financial Synergies:
- Waters projects $200 million cost synergies within 3 years and $290–345 million of revenue-related profit upside by 2030.
- Expected adjusted operating margin >27%, with a path to 500 bps margin expansion by 2030.
- Combined revenue forecast: ~$6.5 billion in 2025, growing to ~$9 billion by 2030.
Leadership & Governance:
- CEO Udit Batra will lead the new entity; CFO Amol Chaubal becomes SVP & CFO.
- Up to two BD designees will join the Waters board, post-close.
- Headquarters remains in Milford, Massachusetts, under the Waters name and ticker (NYSE: WAT).
Strategic Rationale & Sector Impact
For Waters:
- The deal nearly doubles its total addressable market to ~$40 billion, expanding into diagnostics, flow cytometry, microbiology, and clinical testing.
- Adds a large installed base, ~70,000 BD instruments, with 20,000 due for replacement in two years, fueling consumables and recurring-service revenue.
- Enhances scale and margins, positioning Waters closer in size to industry peers like Danaher and Thermo Fisher.
For BD:
- Streamlines operations by shedding a non-core division, allowing deeper focus on medical devices, drug delivery systems, and COVID-era growth engines like pre‑filled syringes.
- Uses cash proceeds (≥ $4 billion) to repurchase shares and deliver the balance sheet, strengthening capital allocation flexibility.
Risks & Market Sentiment
Investor reaction was muted to negative:
- Waters stock fell ~10–13 %, while BD also declined ~1–2 % post-announcement.
- Market concerns include integration complexity, execution risk, shareholder dilution, and the added $4 billion debt load.
- Worries also stem from declining U.S. government research funding, which previously supported nearly 45 % of BD’s biosciences revenue.
Sector Implications
- The combination redefines the life sciences tools and diagnostics landscape, creating a more diversified and vertically integrated player.
- Positioned to compete more aggressively with legacy leaders like Danaher, Thermo Fisher, and Roche in regulated high‑volume testing.
- With strong R&D capabilities and complementary product lines, the merged company can accelerate innovation in bioseparations, clinical diagnostics, and multiomics.
- There may be regulatory scrutiny over market concentration, but the two companies appear to complement rather than overlap heavily.
Conclusion
Overall, this is a strategically compelling, well‑structured transaction. The use of a Reverse Morris Trust gives BD tax efficiency, while Waters gains scale, a broadened product portfolio, and deeper recurring revenue streams. The synergies and growth projections are credible, though realization depends heavily on smooth integration, debt management, and market execution.
If executed effectively, the deal positions Waters as an heir apparent to the top rung of life science tools and diagnostics providers, enhancing innovation, margin expansion, and customer reach. However, near‑term investor concerns about dilution, integration complexity, and macro‑economic headwinds should not be dismissed.
Waters’ calculated leap transforms its footprint in diagnostic and bioscience markets—and sets the stage for a reshaped competitive dynamic in the broader life‑science and clinical testing industry.